These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 2340838

  • 21. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG, Mosbach PA, Kelly MR, Thomas CA, Saint Hilaire MH.
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [Abstract] [Full Text] [Related]

  • 22. Sinemet CR in Parkinson's disease.
    Pfeiffer RF, Wilken KE, Glaeske CS, Hofman R.
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [Abstract] [Full Text] [Related]

  • 23. An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease.
    Friedman JH, Lannon MC.
    Clin Neuropharmacol; 1989 Jun; 12(3):220-3. PubMed ID: 2743346
    [Abstract] [Full Text] [Related]

  • 24. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA, Gilhus NE.
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [Abstract] [Full Text] [Related]

  • 25. Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.
    Ming A, Temlett JA, Fritz VU.
    J Intern Med; 1991 Aug; 230(2):113-7. PubMed ID: 1865161
    [Abstract] [Full Text] [Related]

  • 26. The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
    Rodnitzky RL.
    Neurology; 1992 Jan; 42(1 Suppl 1):44-50; discussion 57-60. PubMed ID: 1549201
    [Abstract] [Full Text] [Related]

  • 27. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
    Kleedorfer B, Poewe W.
    J Neural Transm Park Dis Dement Sect; 1992 Jan; 4(2):173-8. PubMed ID: 1571080
    [Abstract] [Full Text] [Related]

  • 28. Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
    Karstaedt PJ, Pincus JH, Coughlin SS.
    Arch Neurol; 1991 Apr; 48(4):402-5. PubMed ID: 2012514
    [Abstract] [Full Text] [Related]

  • 29. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG, Tanner CM, Gilley DW, Klawans HL.
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [Abstract] [Full Text] [Related]

  • 30. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O'Connell M, Gupta S, IPX066 ADVANCE-PD investigators.
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [Abstract] [Full Text] [Related]

  • 31. Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
    Deleu D, Jacques M, Michotte Y, Ebinger G.
    Clin Neurol Neurosurg; 1989 Apr; 91(4):303-9. PubMed ID: 2555090
    [Abstract] [Full Text] [Related]

  • 32. A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
    Diamond SG, Markham CH, Treciokas LJ.
    Ann Neurol; 1978 Mar; 3(3):267-72. PubMed ID: 352236
    [Abstract] [Full Text] [Related]

  • 33. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.
    Clin Neuropharmacol; 2009 Mar; 32(4):189-92. PubMed ID: 19620848
    [Abstract] [Full Text] [Related]

  • 34. An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
    Olanow CW, Nakano K, Nausieda P, Tetrud JA, Manyam B, Last B, Block G, Liss C, Bush D.
    Clin Neuropharmacol; 1991 Jun; 14(3):235-40. PubMed ID: 2070363
    [Abstract] [Full Text] [Related]

  • 35. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009 Jun; 109(1):51-4. PubMed ID: 19156087
    [Abstract] [Full Text] [Related]

  • 36. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P, Fierro A, Reyes-Parada M, Sáez-Briones P.
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [Abstract] [Full Text] [Related]

  • 37. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
    Hempel AG, Wagner ML, Maaty MA, Sage JI.
    Ann Pharmacother; 1998 Sep; 32(9):878-83. PubMed ID: 9762373
    [Abstract] [Full Text] [Related]

  • 38. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
    LeWitt PA.
    Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
    [Abstract] [Full Text] [Related]

  • 39. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.
    Koller WC, Hutton JT, Tolosa E, Capilldeo R.
    Neurology; 1999 Sep 22; 53(5):1012-9. PubMed ID: 10496260
    [Abstract] [Full Text] [Related]

  • 40. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
    Bowes SG, Dobbs RJ, Henley M, Charlett A, O'Neill CJ, Nicholson PW, Purkiss AG, Weller C, Dobbs SM.
    Eur J Clin Pharmacol; 1992 Sep 22; 43(5):483-9. PubMed ID: 1483485
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.